Welcome to our dedicated page for Singular Genomics Systems news (Ticker: OMIC), a resource for investors and traders seeking the latest updates and insights on Singular Genomics Systems stock.
Singular Genomics Systems, Inc. (OMIC) drives innovation in next-generation sequencing and multiomics technologies, empowering researchers and clinicians worldwide. This dedicated news hub provides investors and industry professionals with essential updates on the company's scientific advancements and market developments.
Access real-time information about OMIC's sequencing platform innovations, strategic partnerships, and regulatory milestones. Our curated collection includes earnings reports, product launch announcements, and research collaborations - all critical for understanding the company's position in the competitive genomics sector.
Key updates cover commercial deployments of the G4 sequencing system, spatial biology breakthroughs, and leadership changes impacting OMIC's growth trajectory. Bookmark this page for streamlined tracking of operational developments that shape precision medicine and life science research.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) announced it will report its Q1 2023 financial results after market close on May 9, 2023. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results.
The company specializes in next-generation sequencing and multiomics technologies, with the G4 Sequencing Platform available commercially, enabling fast and accurate genomic sequencing. Additionally, the PX system is under development, focusing on in situ readouts for RNA and proteins in cells and tissues.
For investors interested in the conference call, a live and archived webcast can be accessed through the company’s investor portal.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) reported its fourth quarter and full-year results for 2022, marking a pivotal year with significant milestones. The company achieved its first revenue of $765,000, primarily from three instrument placements. Operating expenses rose to $22.5 million in Q4 2022, driven by increased headcount and infrastructure for the G4 launch. Despite a net loss of $21.1 million in Q4, the loss per share improved to $0.29 from $0.27 year-over-year. For the full year, revenue totaled $765,000, while the net loss decreased to $90.9 million, or $1.28 per share, compared to $2.10 in 2021. Cash reserves stood at $244.6 million.
Singular Genomics Systems (Nasdaq: OMIC) has announced its participation at Cowen’s 43rd Annual Health Care Conference in Boston on March 7, 2023. The company's management will engage in a fireside chat at 8:10 a.m. PT / 11:10 a.m. ET. Interested investors can access a live and recorded webcast of this presentation through their investor relations website.
Singular Genomics is advancing life science technology with its G4 Sequencing Platform and developing the PX system, aiming to enhance research and clinical outcomes through next-generation sequencing and multiomics technologies.
FAQ
What is the current stock price of Singular Genomics Systems (OMIC)?
What is the market cap of Singular Genomics Systems (OMIC)?
